Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Mizobuchi M et al. | Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. | 2007 | Kidney Int. | pmid:17597697 |
Joy MS et al. | Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment. | 2007 | J Manag Care Pharm | pmid:17605511 |
Fryer RM et al. | Differential inhibition of renin mRNA expression by paricalcitol and calcitriol in C57/BL6 mice. | 2007 | Nephron Physiol | pmid:17622742 |
Repo JM et al. | Paricalcitol aggravates perivascular fibrosis in rats with renal insufficiency and low calcitriol. | 2007 | Kidney Int. | pmid:17667981 |
Chertow GM et al. | Cinacalcet hydrochloride (Sensipar) in hemodialysis patients on active vitamin D derivatives with controlled PTH and elevated calcium x phosphate. | 2006 | Clin J Am Soc Nephrol | pmid:17699221 |
Wu-Wong JR et al. | Elevated phosphorus modulates vitamin D receptor-mediated gene expression in human vascular smooth muscle cells. | 2007 | Am. J. Physiol. Renal Physiol. | pmid:17715259 |
Huybers S and Bindels RJ | Vascular calcification in chronic kidney disease: new developments in drug therapy. | 2007 | Kidney Int. | pmid:17805315 |
Brancaccio D et al. | Vitamin D receptor activator selectivity in the treatment of secondary hyperparathyroidism: understanding the differences among therapies. | 2007 | Drugs | pmid:17883283 |
Andress D | Nonclassical aspects of differential vitamin D receptor activation: implications for survival in patients with chronic kidney disease. | 2007 | Drugs | pmid:17883284 |
Ross EA et al. | Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis. | 2008 | Am. J. Nephrol. | pmid:17914251 |